Considering that leukemia cells are better targets for alloreactive T cells than epithelial cells (which are targeted in GVHD), the ability of CD73 blockade to mitigate GVHD and simultaneously prevent GVL loss rests on achieving an appropriate balance between these effects. Here, NT5E is linked to graft versus host disease.